Clinical trials: Pharmacotherapy
Ototoxicity
Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment
The purpose of this study is to evaluate whether DB-020 administered via an injection in the middle ear prevents hearing loss in participants who will receive high doses of cisplatin as part of their treatment for cancer.
- Trial name
- NCT04262336
- Testing
- DB-020
- Where
- 8 sites in United States, Australia
- Volunteers
- 22 people
- Sponsor
- Decibel Therapeutics
Precision Cells, Chemotherapy
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Objectives: To evaluate the safety and effectiveness of cell therapy using precision cells to treat Advanced Lung Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age…
- Conditions
- Precision Cells, Chemotherapy, Advanced Lung Cancer
- Trial name
- NCT02862587
- Testing
- Chemotherapy, precision cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai International Medical Center
Melanoma
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination chemotherapy of investigator's choice in…
- Trial name
- NCT06008106
- Testing
- tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Urothelial Cancer
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy…
- Trial name
- CheckMate901 (NCT03036098)
- Testing
- Nivolumab, Ipilimumab, Gemcitabine
- Where
- 174 sites in United States, Argentina and 28 more
- Volunteers
- 1,314 people
- Sponsor
- Bristol-Myers Squibb
HR+HER2- Breast Cancer
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after…
- Trial name
- NCT06343948
- Testing
- BL-B01D1, Eribulin, Vinorelbine
- Where
- China
- Volunteers
- 383 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Chemotherapy-induced Neutropenia
A Safety and PK Study of EC-18 in Healthy Subjects
The purpose of this study is to determine if EC-18 is safe and tolerable in healthy subjects.
- Trial name
- NCT02496143
- Testing
- EC-18
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Enzychem Lifesciences Corporation
HIV Infections
A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive
To compare the proportion of patients whose plasma HIV-1 RNA level falls and remains below the limit of quantification by the Roche Amplicor Monitor (400 copies/ml)[AS PER AMENDMENT 8/4/98: 50 copies/ml] between weeks 0 and 24.
- Trial name
- NCT00002215
- Testing
- Emivirine, Nelfinavir mesylate
- Where
- United States
- Sponsor
- Triangle Pharmaceuticals
Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell…
- Trial name
- NCT06736418
- Testing
- 225Ac-ABD147
- Where
- 12 sites in United States
- Volunteers
- 17 people
- Sponsor
- Abdera Therapeutics Inc.
Chemotherapy-induced Peripheral Neuropathy
A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)
The primary objective of the study is: to assess the safety and tolerability of multiple oral (twice daily [BID]) doses of TRK-750 in oxaliplatin-treated colorectal cancer patients with chemotherapy-induced peripheral neuropathy…
- Trial name
- NCT04282590
- Sponsor
- Toray Industries, Inc
Fungal Infection
ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia
Due to the poor outcome of patients with invasive fungal infections (IFI), a more effective prevention of these infections in such patients is wanted.
- Trial name
- NCT00386997
- Testing
- liposomal amphotericin B (AmBisome®)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Carcinoma, Non-Small-Cell Lung
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting.
- Trial name
- NCT03456076
- Testing
- Alectnib, Cisplatin, Vinorelbine
- Where
- 114 sites in United States, Australia and 25 more
- Volunteers
- 257 people
- Sponsor
- Hoffmann-La Roche
Small Cell Lung Carcinoma
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
This is the first study where BAY1000394 is given in combination with chemotherapy: cisplatin / etoposide or carboplatin / etoposide. Patients with small cell lung cancer will be treated.
- Trial name
- NCT01573338
- Testing
- Roniciclib (BAY1000394), Etoposide, Cisplatin
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 43 people
- Sponsor
- Bayer
Cervical Cancer
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.
- Trial name
- NCT06755515
- Testing
- Rulonilimab, cisplatin/carboplatin + paclitaxel ± bevacizumab
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Gastric Cancer
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer
The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced…
- Trial name
- NCT00952497
- Testing
- Cisplatin, Capecitabine, Telatinib
- Where
- 11 sites in United States, Spain
- Volunteers
- 48 people
- Sponsor
- ACT Biotech, Inc
Chemotherapy-induced Thrombocytopenia
Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia
To evaluate the efficacy and safety of QL0911 to prevention chemotherapy-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood.
- Trial name
- NCT05554913
- Testing
- QL0911
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Diabetes Mellitus
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
- Trial name
- NCT00306384
- Testing
- Alogliptin
- Where
- 114 sites in United States, Argentina and 10 more
- Volunteers
- 3,323 people
- Sponsor
- Takeda
Non Small Cell Lung Cancer, Breast Cancer
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy and safety, comparing to PEG-rhG-CSF, once-per-cycle, in chemotherapy-induced neutropenia
- Trial name
- NCT02005458
- Testing
- YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
- Where
- 12 sites in China
- Volunteers
- 80 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
This 2 arm study will compare the efficacy and safety of Tarceva plus Avastin, and chemotherapy plus Avastin, in the first-line treatment of patients with advanced non-small cell lung cancer.
- Trial name
- NCT00531960
- Testing
- Erlotinib, Bevacizumab, Standard platinum-based chemotherapy
- Where
- 57 sites in Australia, Belgium and 11 more
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Febrile Neutropenia, Neutropenia
Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients
Febrile neutropenia (FN) is a major life-threatening treatment complication in cancer patients undergoing intensive chemotherapy. Endogenous flora is considered to be one of the main sources of infections during neutropenia.
- Conditions
- Febrile Neutropenia, Neutropenia, Infection in an Immunocompromised Host, Cancer
- Trial name
- FENSY (NCT02544685)
- Testing
- Probio-Fix Inum, Beneo Synergy 1
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- S&D Pharma SK s.r.o.
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer.
- Trial name
- NCT02005549
- Testing
- bevacizumab [Avastin], docetaxel, capecitabine [Xeloda]
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche